How Europe’s energy crisis is impacting pharma

Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.

By Karissa Waddick • Nov. 2, 2022

Developing a channel strategy that optimizes gross to net

Today, pharma manufacturers face unprecedented GTN challenges. To unlock sustainable brand growth, a value-aligned channel strategy is pivotal.

Oct. 31, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

By Meagan Parrish • Oct. 25, 2022

5 impactful drug trial failures from the last year

Major recent trial flops and what they mean for companies, patients and the industry.

By Meagan Parrish • Oct. 19, 2022

C-suite shake-ups at 23andMe, Moderna signal new stages of growth

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Oct. 5, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

4 ways to nail the launch of your cell therapy

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

By Meagan Parrish • Aug. 10, 2022

The ‘alarming’ spread of Monkeypox — by the numbers

With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

By Meagan Parrish • Aug. 8, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

A glimpse inside Bristol Myers Squibb’s integration with Celgene

Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

By Meagan Parrish • Aug. 1, 2022

Pfizer's former R&D head takes on drug pricing misconceptions in new book

John LaMattina has something to say about the industry — and he hopes patients are listening.

By Meagan Parrish • July 19, 2022

Anjarium Biosciences’ CEO on its next-gen gene therapies

Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

By Kim Ribbink • July 15, 2022

The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

By Meagan Parrish • July 7, 2022

Dave Ross of Seqirus talks 'milestone' influenza vax vote

In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time. 

By Alexandra Pecci • July 5, 2022

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

Why biomanufacturing is the next innovation frontier for genomic therapies

While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

By Meagan Parrish • June 13, 2022

SIGA prepares to kick production for monkeypox treatment into high gear

‘We’re not bored,’ the company’s science chief says as SIGA Technologies looks to ramp up supplies of its therapeutic.

By Meagan Parrish • May 31, 2022

A potential COVID-19 EUA could turn this small biotech into a household name

Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.

By Meagan Parrish • May 19, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

Right-sizing the channel strategy for maximum impact

Failure to right-size your distribution model imposes financial penalties and wasted expenditures.

May 9, 2022

Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine

After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.

By Taren Grom , Karissa Waddick • May 4, 2022

From the fringes to the forefront — the mRNA era has taken hold of pharma

A look at what’s next for the industry’s buzziest technology.

By Kim Ribbink • April 22, 2022

A pharma mystery: Cancer-causing impurities drive joint search for answers

Pharmaceutical industry insiders and regulators are striving to overcome the ‘blind spots’ that contribute to nitrosamine contamination.

By Michael Gibney • April 19, 2022